Bioinformatics and Computational Biology in Drug Discovery and Development

Herausgeber: Loging, William T.

• Gebundenes Buch

Produktbeschreibung

Computational biology drives discovery through its use of high-throughput informatics approaches. This book provides a road map of the current drug development process and how computational biology approaches play a critical role across the entire drug discovery pipeline. Through the use of previously unpublished, real-life case studies the impact of a range of computational approaches are discussed at various phases of the pipeline. Additionally, a focus section provides innovative visualisation approaches, from both the drug discovery process as well as from other fields that utilise large datasets, recognising the increasing use of such technology. Serving the needs of early career and more experienced scientists, this up-to-date reference provides an essential introduction to the process and background of drug discovery, highlighting how computational researchers can contribute to that pipeline.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Seitenzahl: 254
• Erscheinungstermin: 2. Januar 2018
• Englisch
• Abmessung: 250mm x 175mm x 18mm
• Gewicht: 624g
• ISBN-13: 9780521768009
• ISBN-10: 0521768004
• Artikelnr.: 44124056

Inhaltsangabe

Foreword; Preface: the future of drug discovery and health care Eric
Schadt; 1. The art and science of the Drug Discovery Pipeline (DDP) William
T. Loging; 2. Computational approaches to drug target identification Thomas
B. Freeman and Pek Lum; 3. Understanding human disease knowledge through
text mining Raul Rodriguez-Esteban; 4. Integrating translational biomarkers
into drug development Jonathan Phillips; 5. Computational phenotypic
assessment of small molecules in drug discovery William T. Loging and
Thomas B. Freeman; 6. Data visualization and the DDP process Ke Xu; 7.
Information visualization - important IT considerations Telmo Silva; 8. The
New Drug Application (NDA) and regulatory approval stages William T.
Loging, Marilyn Lewis, Bryn Williams-Jones and Roy Mansfield; 9. Clinical
trial failures and drug repositioning Mark Crawford and Jeff Handler;
Appendix I. Additional knowledge-based analysis approaches Raul
Rodriguez-Esteban; Appendix II. Open source tools and public data sources
Yirong Wang and William T. Loging; Index.